Literature DB >> 27592409

Ala5-galanin (2-11) is a GAL2R specific galanin analogue.

Kristin Webling1, Johan Runesson2, Andreas Lang3, Indrek Saar4, Barbara Kofler3, Ülo Langel5.   

Abstract

It is over 30years since the regulatory peptide galanin was discovered by Professor Mutt and co-workers. Galanin exerts its effects by binding to three galanin G-protein coupled receptors, namely GAL1R, GAL2R and GAL3R. Each galanin receptor has a different distribution in the central nervous system and the peripheral nervous system as well as distinctive signaling pathways, which implicates that the receptors are involved in different biological- and pathological effects. The delineation of the galaninergic system is however difficult due to a lack of stable, specific galanin receptor ligands. Herein, a new short GAL2R specific ligand, Ala5-galanin (2-11), is presented. The galanin (2-11) modified analogue Ala5-galanin (2-11) was tested in 125I-galanin competitive binding studies for the three galanin receptors and the G-protein coupled receptor signaling properties was tested by the ability to influence second-messenger molecules like inositol phosphate and cyclic adenosine monophosphate. In addition, two different label-free real-time assays, namely EnSpire® based on an optical biosensor and xCELLigence® based on an electric biosensor, were used for evaluating the signaling properties using cell lines with different levels of receptor expression. Ala5-galanin (2-11) was subsequently found to be a full agonist for GAL2R with more than 375-fold preference for GAL2R compared to both GAL1R and GAL3R. The single amino acid substitution of serine to alanine at position 5 in the short ligand galanin (2-11) resulted in a ligand subsequently unable to bind neither GAL3R nor GAL1R, even at concentrations as high as 0.1mM.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Agonist; Dynamic mass redistribution; GAL(2)R specific ligand; GPCR; Galanin; Impedance; Label-free real-time assay; Neuropeptide

Mesh:

Substances:

Year:  2016        PMID: 27592409     DOI: 10.1016/j.npep.2016.08.008

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Myocardial protection from ischemia/reperfusion injury by exogenous galanin fragment.

Authors:  Andrei Timotin; Oleg Pisarenko; Maria Sidorova; Irina Studneva; Valentin Shulzhenko; Marina Palkeeva; Larisa Serebryakova; Aleksander Molokoedov; Oksana Veselova; Mathieu Cinato; Helene Tronchere; Frederic Boal; Oksana Kunduzova
Journal:  Oncotarget       Date:  2017-03-28

2.  Increased Serum Neuropeptide Galanin Level Is a Predictor of Cognitive Dysfunction in Patients with Hip Fracture.

Authors:  Zichao Xue; Ke Zhang; Biao Luo; Long Fan; Ruizhe Zhao; Guangliang Hu
Journal:  Dis Markers       Date:  2021-12-10       Impact factor: 3.434

3.  Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake.

Authors:  Anneke Kuipers; Márta Balaskó; Erika Pétervári; Andreas Koller; Susanne M Brunner; Gert N Moll; Barbara Kofler
Journal:  Neurotherapeutics       Date:  2021-12-02       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.